< Back to previous page
Researcher
Philip Van Damme
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
- See also: Philip Van Damme (Flanders Institute for Biotechnology)
Affiliations
- Van Den Bosch Lab (Research group)
Member
From1 Jan 2017 → Today - Laboratory for Neurobiology (VIB-KU Leuven) (Lab)
Member
From1 Jan 2012 → Today - Research Group Experimental Neurology (Division)
Member
From1 Oct 2000 → 31 Dec 2011
Projects
1 - 10 of 49
- Towards mechanistic biomarkers for amyotrophic lateral sclerosisFrom1 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mapping the microglial heterogeneity in C9orf72-ALS and sporadic ALS using single cell profilingFrom1 Nov 2023 → TodayFunding: BOF - postdoctoral mandates
- A multi-modal and longitudinal approach to study the neurobiological underpinnings of disease onset and progression in genetic ALS variants: from presymptomatic to symptomatic disease stages.From1 Oct 2023 → TodayFunding: FWO junior postdoctoral fellowship
- HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutationsFrom19 Apr 2023 → 31 Dec 2023Funding: Foundations, funds and other with scientific goal
- Measuring brain activation non-invasively in freely moving healthy and neuropsychiatric human populations using functional near-infrared spectroscopy (fNIRS)From1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Investigating the role of cilia dysfunction in Amyotrophic Lateral SclerosisFrom1 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mechanisms of motor neuron degeneration in amyotrophic lateral sclerosis (ALS): cell death pathways and/or aberrant communication between cell body and neuromuscular junctionsFrom1 Oct 2022 → TodayFunding: BOF - projects
- A multi-modal approach to study C9orf72-mediated diseaseFrom16 May 2022 → 15 May 2023Funding: BOF - postdoctoral mandates
- Biomarkers in asymptomatic carriers of ALS-related mutationsFrom1 Apr 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding lysosomal dysfunction in the frontotemporal dementiaamyotrophic lateral sclerosis spectrum of neurodegenerative disorders.From1 Jan 2022 → TodayFunding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 341
- The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials(2024)
Authors: Philip Van Damme
- European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD)(2024)
Authors: Philip Van Damme
- The sense of antisense therapies in ALS.(2024)
Authors: Philip Van Damme, Ludo Van Den Bosch
Pages: 252 - 262 - TUBA4A downregulation as observed in ALS post-mortem motor cortex causes ALS-related abnormalities in zebrafish(2024)
Authors: Philip Van Damme, Dietmar Thal, Valérie Bercier, Ludo Van Den Bosch
- PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport.(2024)
Authors: Thibaut Burg, Philip Van Damme, Ludo Van Den Bosch
Pages: 41 - Prognostic value of motor and extramotor involvement in ALS(2024)
Authors: Fouke Ombelet, Frederik Hobin, Joke De Vocht, Philip Van Damme
Pages: 67 - 74 - A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial(2023)
Authors: Philip Van Damme
- SorCS2 binds progranulin to regulate motor neuron development(2023)
Authors: Philip Van Damme
- TDP‑43 pathology is associated with increased tau burdens and seeding(2023)
Authors: Sandra Oliveira Tomé, Grigoria Tsaka, Klara Gawor, Philip Van Damme, Ludo Van Den Bosch, Rik Vandenberghe, Frederic Rousseau, Joost Schymkowitz, Dietmar Thal
- The role of glial cells in sALS and C9orf72 HRE-mediated ALS(2023)
Authors: Pegah Masrori, Philip Van Damme, An Goris